Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes

Journal of Controlled Release

Volumn 217, Issue , 2015, Pages 345-351

  Pardi, Norbert ^a   Tuyishime, Steven ^a   Muramatsu, Hiromi ^a   Kariko, Katalin ^a   Mui, Barbara L ^b   Tam, Ying K ^b   Madden, Thomas D ^b   Hope, Michael J ^b   Weissman, Drew ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Acuitas Therapeutics   (Canada)

Author keywords

Luciferase; mRNA; Nanoparticle; Non viral gene delivery; Pseudouridine

Indexed keywords

GENE TRANSFER; MAMMALS; NANOPARTICLES; PROTEINS; RNA;

INTRADERMAL INJECTION; LUCIFERASE; MESSENGER RNAS (MRNA); MRNA; NON-VIRAL GENE DELIVERY; PSEUDOURIDINE; SHORT INTERFERING RNA; THERAPEUTIC PROTEIN;

NUCLEIC ACIDS;

1 METHYLPSEUDOURIDINE; LIPID NANOPARTICLE; LIPOFECTIN; LUCIFERASE; MESSENGER RNA; NANOPARTICLE; PSEUDOURIDINE; UNCLASSIFIED DRUG; 1,2-DIELAIDOYLPHOSPHATIDYLETHANOLAMINE; 1-METHYLPSEUDOURIDINE; FIREFLY LUCIFERASE; PHOSPHATIDYLETHANOLAMINE;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CODON; CONTROLLED STUDY; DENDRITIC CELL; DRUG ADMINISTRATION ROUTE; DRUG HALF LIFE; EMBRYO; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMORTALIZED CELL LINE; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATRACHEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL; MOUSE; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIMARY CELL; PRIORITY JOURNAL; RNA TRANSLATION; SUBCUTANEOUS DRUG ADMINISTRATION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CHEMISTRY; GENETICS; HEK293 CELL LINE; KINETICS; LUNG; METABOLISM; PROCEDURES;

ANIMALS; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HEK293 CELLS; HUMANS; KINETICS; LUCIFERASES, FIREFLY; LUNG; MICE, INBRED BALB C; NANOPARTICLES; PHOSPHATIDYLETHANOLAMINES; PSEUDOURIDINE; RNA, MESSENGER; TRANSFECTION;

EID: 84945466813     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.08.007     Document Type: Article

References (27)

1. G.F. Jirikowski, P.P. Sanna, D. Maciejewski-Lenoir, and F.E. Bloom Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA Science 255 1992 996 998
2. K. Kariko, and et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability Mol. Ther. 16 2008 1833 1840 10.1038/mt.2008.200
3. U. Sahin, K. Kariko, and O. Tureci mRNA-based therapeutics - developing a new class of drugs Nat. Rev. Drug Discov. 13 2014 759 780 10.1038/nrd4278
4. D. Weissman mRNA transcript therapy Expert Rev. Vaccines 14 2015 265 281 10.1586/14760584.2015.973859
5. K. Kariko, M. Buckstein, H. Ni, and D. Weissman Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA Immunity 23 2005 165 175 10.1016/j.immuni.2005.06.008
6. B. Weide, and et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients J. Immunother. 32 2009 498 507 10.1097/CJI.0b013e3181a00068
7. M. Jayaraman, and et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo Angew. Chem. 51 2012 8529 8533 10.1002/anie.201203263
8. M.A. Maier, and et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics Mol. Ther. 21 2013 1570 1578 10.1038/mt.2013.124
9. A. Akinc, and et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics Nat. Biotechnol. 26 2008 561 569 10.1038/nbt1402
10. K.T. Love, and et al. Lipid-like materials for low-dose, in vivo gene silencing Proc. Natl. Acad. Sci. U. S. A. 107 2010 1864 1869 10.1073/pnas.0910603106
11. A.J. Geall, and et al. Nonviral delivery of self-amplifying RNA vaccines Proc. Natl. Acad. Sci. U. S. A. 109 2012 14604 14609 10.1073/pnas.1209367109
12. A. Hekele, and et al. Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice Emerg. Microbes Infect. 2 2013 e52 10.1038/emi.2013.54
13. L.A. Brito, and et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines Mol. Ther. 22 2014 2118 2129 10.1038/mt.2014.133
14. N. Pardi, H. Muramatsu, D. Weissman, and K. Kariko In vitro transcription of long RNA containing modified nucleosides Methods Mol. Biol. 969 2013 29 42 10.1007/978-1-62703-260-5-2
15. D. Weissman, N. Pardi, H. Muramatsu, and K. Kariko HPLC purification of in vitro transcribed long RNA Methods Mol. Biol. 969 2013 43 54 10.1007/978-1-62703-260-5-3
16. E. Machholz, G. Mulder, C. Ruiz, B.F. Corning, and K.R. Pritchett-Corning Manual restraint and common compound administration routes in mice and rats J. Vis. Exp. 2012 10.3791/2771
17. S. Das, K. MacDonald, H.Y. Chang, and W. Mitzner A simple method of mouse lung intubation J. Vis. Exp. 2013 e50318 10.3791/50318
18. K. Kariko, H. Muramatsu, J. Ludwig, and D. Weissman Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA Nucleic Acids Res. 39 2011 e142 10.1093/nar/gkr695
19. A. Akinc, and et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms Mol. Ther. 18 2010 1357 1364 10.1038/mt.2010.85
20. X. Yan, and et al. The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse Biochem. Biophys. Res. Commun. 328 2005 57 62 10.1016/j.bbrc.2004.12.137
21. T. Geiger, A. Wehner, C. Schaab, J. Cox, and M. Mann Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins Mol. Cell. Proteomics 11 2012 10.1074/mcp.M111.014050 (M111 014050)
22. J.F. Thompson, L.S. Hayes, and D.B. Lloyd Modulation of firefly luciferase stability and impact on studies of gene regulation Gene 103 1991 171 177
23. P. Midoux, and C. Pichon Lipid-based mRNA vaccine delivery systems Expert Rev. Vaccines 14 2015 221 234 10.1586/14760584.2015.986104
24. B. Petsch, and et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza a virus infection Nat. Biotechnol. 30 2012 1210 1216 10.1038/nbt.2436
25. M. Fotin-Mleczek, and et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity J. Immunother. 34 2011 1 15 10.1097/CJI.0b013e3181f7dbe8
26. S.T. Adams Jr., and S.C. Miller Beyond D-luciferin: expanding the scope of bioluminescence imaging in vivo Curr. Opin. Chem. Biol. 21 2014 112 120 10.1016/j.cbpa.2014.07.003
27. K.K. Phua, K.W. Leong, and S.K. Nair Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format J. Control. Release 166 2013 227 233 10.1016/j.jconrel.2012.12.029